Compare · ABSI vs BIAF
ABSI vs BIAF
Side-by-side comparison of Absci Corporation (ABSI) and bioAffinity Technologies Inc. (BIAF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and BIAF operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI is the larger of the two at $1.50B, about 328.3x BIAF ($4.6M).
- Over the past year, ABSI is up 68.9% and BIAF is down 92.7% - ABSI leads by 161.7 points.
- BIAF has been more active in the news (20 items in the past 4 weeks vs 6 for ABSI).
- ABSI has more recent analyst coverage (21 ratings vs 0 for BIAF).
PerformanceABSI+68.93%BIAF-92.75%
2025-10-16+0.00%2026-10-16
- Company
- Absci Corporation
- bioAffinity Technologies Inc.
- Price
- $8.18-7.88%
- $3.70-7.50%
- Market cap
- $1.50B
- $4.6M
- 1M return
- -11.29%
- -58.66%
- 1Y return
- +68.93%
- -92.75%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2022
- News (4w)
- 6
- 20
- Recent ratings
- 21
- 0
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)
- Absci to Participate in Upcoming Investor Conferences
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
Latest BIAF
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- SEC Form PRER14A filed by bioAffinity Technologies Inc.
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form 424B5 filed by bioAffinity Technologies Inc.
- bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form 424B5 filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules